TABLE 2.
NKG2C allele and genotype frequencies in people living with HIV and HIV-exposed seronegative subjectsa
| NKG2C allotype/genotype | Frequency of allele or genotype in population |
OR | 95% CI | P value | |
|---|---|---|---|---|---|
| PLWH | HESN | ||||
| All, n | 434 | 157 | |||
| Allele frequency, % | |||||
| nkg2c+ | 80.5 | 80.9 | 1.0 | 0.5–2.1 | 1.00 |
| nkg2c− | 19.5 | 19.1 | |||
| Genotype frequency, no. (%) | |||||
| NKG2C+/+ | 276 (63.6) | 97 (61.8) | 1.1 | 0.7–1.6 | 0.70 |
| NKG2C+/− | 147 (33.9) | 60 (38.2) | 0.8 | 0.6–1.2 | 0.38 |
| NKG2C−/− | 11 (2.5) | 0 | 8.6** | 0.5–146.0** | 0.04* |
| NKG2C+/− + NKG2C−/− | 158 (36.4) | 60 (38.2) | 0.9 | 0.6–1.5 | 0.70 |
| Sexually exposed, n | 371 | 78 | |||
| Allele frequency, % | |||||
| nkg2c+ | 81.4 | 78.2 | 1.21 | 0.6–2.4 | 0.72 |
| nkg2c− | 18.6 | 21.9 | |||
| Genotype frequency, no. (%) | |||||
| NKG2C+/+ | 240 (64.7) | 44 (56.4) | 1.4 | 0.9–2.3 | 0.20 |
| NKG2C+/− | 124 (33.4) | 34 (43.6) | 0.6 | 0.4–1.1 | 0.09 |
| NKG2C−/− | 7 (1.9) | 0 | 3.2** | 0.2–57.2** | 0.61* |
| IDUs, n | 63 | 79 | |||
| Allele frequency, % | |||||
| nkg2c+ | 75.4 | 83.5 | 0.6 | 0.3–1.2 | 0.21 |
| nkg2c− | 24.6 | 16.5 | |||
| Genotype frequency, no. (%) | |||||
| NKG2C+/+ | 36 (57.1) | 53 (67.1) | 0.6 | 0.3–1.3 | 0.29 |
| NKG2C+/− | 23 (36.5) | 26 (32.9) | 1.2 | 0.6–2.3 | 0.72 |
| NKG2C−/− | 4 (6.3) | 0 | 12.0** | 0.6–277.7** | 0.04* |
a
Abbreviations: PLWH, people living with HIV; HESN, HIV-exposed seronegative; OR, odds ratio; 95% CI, 95% confidence interval; IDUs, injection drug users. Asterisks indicate statistical significance measured by Fisher’s exact test (*) with Haldane’s correction (**).